GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Palatin Technologies Inc (LTS:0KF3) » Definitions » Institutional Ownership

Palatin Technologies (LTS:0KF3) Institutional Ownership : 8.13% (As of Jun. 07, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Palatin Technologies Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Palatin Technologies's institutional ownership is 8.13%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Palatin Technologies's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Palatin Technologies's Float Percentage Of Total Shares Outstanding is 98.15%.


Palatin Technologies Institutional Ownership Historical Data

The historical data trend for Palatin Technologies's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Palatin Technologies Institutional Ownership Chart

Palatin Technologies Historical Data

The historical data trend for Palatin Technologies can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 83.59 83.59 9.27 6.51 6.21 8.40 8.57 7.60 8.07 8.13

Palatin Technologies Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Palatin Technologies (LTS:0KF3) Business Description

Traded in Other Exchanges
Address
4B Cedar Brook Drive, Cranbury, NJ, USA, 08512
Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.

Palatin Technologies (LTS:0KF3) Headlines

No Headlines